Trial reportActa pharmaceutica Sinica. B2023
Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial.
Open access · diamondAbstract readClinical Trial
In one paragraph
Trial report in Acta pharmaceutica Sinica. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Efficacy and safety of entinostat plus exemestane in hormone receptor-positive breast cancer: a systematic review meta-analysis of randomized controlled trials.Breast cancer research and treatment · 2025Pooled it
- HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial).Signal transduction and targeted therapy · 2026Trial
- Chidamide combined with fulvestrant in the treatment of HR-positive, HER2-negative advanced breast cancer after failure of previous endocrine therapy: a single-arm, single-center, phase 2 study.Breast cancer research : BCR · 2026Trial
- Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors.The oncologist · 2024Trial
- Method development and validation for determination of entinostat in human plasma and its application in breast cancer patients.RSC advances · 2026Article
- Pharmacological chromatin remodeling enhances response to estrogen therapy in ERMolecular oncology · 2026Article
- Chemical Epigenetics: Small Molecules Targeting Chromatin Modifiers in Disease Modulation.Cell biochemistry and biophysics · 2026Review
- Construction of a Lysine Lactylation- and DNA Damage Repair-Related Gene Signature to Predict the Prognosis and Drug Sensitivity of Breast Cancer Patients.International journal of molecular sciences · 2026Article
- Zinc Affinity of Benzamide-Based Histone Deacetylase Inhibitors: A DFT Study.Molecules (Basel, Switzerland) · 2026Article
- TMEM70 drives breast cancer progression via mitochondrial oxidative phosphorylation and microenvironment remodeling.Cancer cell international · 2026Article
- Targeted Therapies for Each Subtype of Breast Cancer.MedComm · 2026Review
- Steroidogenic Acute Regulatory Protein in Breast Cancer: Mechanistic Insights into Pathogenesis and Therapeutics.International journal of molecular sciences · 2026Review
- Efficacy and safety of treatments in HR+/HER2- advanced breast cancer after CDK4/6 inhibitor progression: a network meta-analysis and scoping review.BMC cancer · 2026Article
- Differential transcriptomic modulation by histone deacetylase inhibitor SAHA in LUAD and LUSC.Clinical epigenetics · 2026Article
- Clinical progress and functional modalities of HDAC inhibitor-based combination therapies in cancer treatment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Decoding breast cancer: insights into molecular pathways & therapeutic approaches.Discover oncology · 2025Review
- Sodium Phenylbutyrate Ameliorates Ovariectomy-Induced Bone Loss in Rats.Medicina (Kaunas, Lithuania) · 2025Article
- Exploring the Impact of Nanotherapeutics on Histone H3 and H4 Acetylation Enrichment in Cancer Epigenome: A Systematic Scoping Synthesis.Epigenomes · 2025Review
- Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: a systematic review and network meta-analysis.EClinicalMedicine · 2025Article
- Current Status and Advances in Anti-Androgen Therapy for Triple-Negative Breast Cancer.Current medical science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 17 institutions in 1 country.
Binghe XuDepartment of Medical Oncology and State Key Laboratory of Molecular Oncology, National Cancer Cener/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Qingyuan ZhangDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150000, China.
Xichun HuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200000, China.
Qing LiDepartment of Medical Oncology and State Key Laboratory of Molecular Oncology, National Cancer Cener/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Tao SunDepartment of Galactophore, Liaoning Cancer Hospital & Institute, Shenyang 110801, China.
Wei LiDepartment of Oncology, the First Hospital of Jilin University, Changchun 130061, China.
Quchang OuyangDepartment of Galactophore, Hunan Cancer Hospital, Changsha 410000, China.
Jingfen WangDepartment of Galactophore, Linyi Cancer Hospital, Linyi 276000, China.
Zhongsheng TongDepartment of Breast Medical Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300000, China.
Min YanDepartment of Breast Disease, Henan Breast Cancer Center, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China.
Huiping LiDepartment of Breast Oncology, Beijing Cancer Hospital, Beijing 100000, China.
Xiaohua ZengBreast Cancer Center, Chongqing University Cancer Hospital, Chongqing 400000, China.
Changping ShanDepartment of Breast and Thyroid Oncology, Affiliated Hospital of Jining Medical University, Changchun 130021, China.
Xian WangDepartment of Medical Oncology, Run Run Shaw Hospital, Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.
Xi YanDepartment of Head and Heck Oncology, West China Hospital, Sichuan University, Chengdu 610000, China.
Jian ZhangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200000, China.
Yue ZhangDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150000, China.
Jiani WangDepartment of Medical Oncology and State Key Laboratory of Molecular Oncology, National Cancer Cener/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Liang ZhangDepartment of Galactophore, Liaoning Cancer Hospital & Institute, Shenyang 110801, China.
Ying LinDepartment of Thyroid & Breast Surgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China.
Jifeng FengDepartment of Medical Oncology, Jiangsu Cancer Hospital, Nanjing 210000, China.
Qianjun ChenDepartment of Galactophore, Guangdong Hospital of Traditional Chinese Medicine, Guangzhou 510000, China.
Jian HuangDepartment of Oncological Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
Lu ZhangTaizhou EOC Pharma Co., Ltd., Taizhou 318000, China.
Lisong YangTaizhou EOC Pharma Co., Ltd., Taizhou 318000, China.
Ying TianTaizhou EOC Pharma Co., Ltd., Taizhou 318000, China.
Hongyan ShangTaizhou EOC Pharma Co., Ltd., Taizhou 318000, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNLiaoning Cancer Hospital & Institute · CNFudan University Shanghai Cancer Center · CNHarbin Medical University · CNHunan Cancer Hospital · CNSun Yat-sen University · CNAffiliated Hospital of Jining Medical University · CNChongqing University · CNGuangdong Provincial Hospital of Traditional Chinese Medicine · CNJiangsu Cancer Hospital · CNJilin University · CNPeking University · CNSichuan University · CNSir Run Run Shaw Hospital · CNTaizhou University · CNTianjin Medical University Cancer Institute and Hospital · CNZhengzhou University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Entinostat plus exemestane in hormone receptor-positive (HR+) advanced breast cancer (ABC) previously showed encouraging outcomes. This multicenter phase 3 trial evaluated the efficacy and safety of entinostat plus exemestane in Chinese patients with HR + ABC that relapsed/progressed after ≥1 endocrine therapy. Patients were randomized (2:1) to oral exemestane 25 mg/day plus entinostat (
Indexed as
Advanced breast cancerHistone deacetylase inhibitorsHormone receptor-positivePhase 3 clinical trial
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.